Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.